Cyclo Therapeutics Inc (CYTH)

$0.72 +0.01 (1.39%)
Market Cap 23.72M
Revenue (ttm) 1.08M
Net Income (ttm) -20.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,857.41%
Debt to Equity Ratio 0.00
Volume 188,200
Avg Vol 1,832,044
Day's Range N/A - N/A
Shares Out 32.92M
Stochastic %K 74%
Beta -0.57
Analysts Sell
Price Target $0.95
DrevanTheStillblade
DrevanTheStillblade Oct. 22 at 6:11 PM
If you’re looking for asymmetric upside with some downside cushion, check out GIPR. Real estate portfolio, no dilution headlines lately, and the chart base is forming right now. This is setup‑ready for a breakout campaign… $DPW $CYTH $VIRI $KGKG $RNWK
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 18 at 1:55 PM
$CDT $CYTH $JAGX $RFL $MDAI !
0 · Reply
SinfulMeatStick
SinfulMeatStick Sep. 17 at 4:14 PM
$CYTH why is everyone still posting here? Cyth is now $RFL
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 17 at 1:15 PM
$CDT finished reverse park job but forward instead of reverse old $CYTH $JAGX move forward 2 hrs lisa on what u r doing * $RFL $MDAI update adjustment
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 26 at 3:50 PM
$VOR me off this 1.10 reverse par job old $CYTH
0 · Reply
DottoreMK
DottoreMK May. 9 at 4:16 PM
$CYTH
0 · Reply
Miko_Vakilla
Miko_Vakilla Apr. 7 at 8:39 PM
$CYTH Form 15! $2.15 here we come. Let's go Mo!
1 · Reply
GDS_investing
GDS_investing Apr. 7 at 6:06 PM
$RFL money on the floor add here today for 5$+ $CYTH
0 · Reply
StreetSlap
StreetSlap Apr. 6 at 7:03 AM
$ANVS $CYTH $CEIN $IMUX $PTPI Lol Nah...great retail hunters, great scammers, but Maria just set the bar to a new low 🐍💃🏻
1 · Reply
ForestFoxes
ForestFoxes Apr. 6 at 12:27 AM
$ANVS $CYTH $CEIN $IMUX $PTPI @StreetSlap🤯 ⁿᵒ ʷᵃʸ ... 🤨 ᵃʳᵉ ʸᵒᵘ ᵗᵉˡˡᶦⁿᵍ ᵐᵉ ᵗʰᵃᵗ ᵗʰᵒˢᵉ ᶜᴱᴼˢ ... ᵃˡˢᵒ ʰᵉˡᵈ ᵃ ᴾᵃᵗᶦᵉⁿᵗˢ' ᴸᶦᵛᵉ ᶠᵒʳᵘᵐ and, told patients and their families to "BUY Stock!" and "That's the ONLY out of it!" 💔 Did those other CEOs also use fiery language in their chat with patients and families with references to Hell repeated??? 🔥🐍😈🔥
1 · Reply
Latest News on CYTH
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Feb 20, 2025, 4:35 PM EST - 8 months ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

RFL

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Feb 7, 2025, 8:05 AM EST - 9 months ago

Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

Jan 14, 2025, 8:05 AM EST - 10 months ago

Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

Dec 20, 2024, 12:15 PM EST - 11 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders

SKGR

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

Nov 21, 2024, 4:13 AM EST - 1 year ago

Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 14, 2024, 8:05 AM EST - 1 year ago

Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Sep 5, 2024, 9:05 AM EDT - 1 year ago

Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

RFL

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

RFL

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 9:00 AM EDT - 1 year ago

Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Jul 29, 2024, 9:05 AM EDT - 1 year ago

Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Jun 25, 2024, 9:25 AM EDT - 1 year ago

Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

May 30, 2024, 9:00 AM EDT - 1 year ago

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 8:05 AM EDT - 1 year ago

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 18, 2024, 9:05 AM EDT - 1 year ago

Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Mar 14, 2024, 9:34 AM EDT - 1 year ago

Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Jan 29, 2024, 9:15 AM EST - 1 year ago

Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Dec 27, 2023, 4:15 PM EST - 1 year ago

Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

Dec 18, 2023, 9:15 AM EST - 2 years ago

Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Nov 28, 2023, 5:19 PM EST - 2 years ago

APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Nov 21, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Nov 15, 2023, 8:05 AM EST - 2 years ago

Cyclo Therapeutics Reports Third Quarter 2023 Financial Results

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Oct 23, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Oct 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics to Present at 8th Annual Dawson James Conference

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Sep 21, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Aug 15, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Reports Second Quarter 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

RFL

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Jun 29, 2023, 1:32 PM EDT - 2 years ago

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Jun 12, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's Disease

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Jun 5, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

RFL

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

May 15, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

May 2, 2023, 8:12 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

RFL

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 21, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Mar 20, 2023, 8:05 AM EDT - 2 years ago

Cyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial Results

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Jan 11, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Jan 10, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Jan 9, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 4, 2023, 4:05 PM EST - 3 years ago

Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Jan 4, 2023, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Dec 30, 2022, 8:00 AM EST - 3 years ago

Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Nov 11, 2022, 8:05 AM EST - 3 years ago

Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Oct 18, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Oct 4, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's Disease

Cyclo Therapeutics Provides Business Update

Sep 28, 2022, 2:02 PM EDT - 3 years ago

Cyclo Therapeutics Provides Business Update

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Aug 16, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Cyclo Therapeutics to Present at the China NPC Association Meeting

Aug 8, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at the China NPC Association Meeting

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

Jul 21, 2022, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022

DrevanTheStillblade
DrevanTheStillblade Oct. 22 at 6:11 PM
If you’re looking for asymmetric upside with some downside cushion, check out GIPR. Real estate portfolio, no dilution headlines lately, and the chart base is forming right now. This is setup‑ready for a breakout campaign… $DPW $CYTH $VIRI $KGKG $RNWK
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 18 at 1:55 PM
$CDT $CYTH $JAGX $RFL $MDAI !
0 · Reply
SinfulMeatStick
SinfulMeatStick Sep. 17 at 4:14 PM
$CYTH why is everyone still posting here? Cyth is now $RFL
1 · Reply
Love_To_Learn
Love_To_Learn Sep. 17 at 1:15 PM
$CDT finished reverse park job but forward instead of reverse old $CYTH $JAGX move forward 2 hrs lisa on what u r doing * $RFL $MDAI update adjustment
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 26 at 3:50 PM
$VOR me off this 1.10 reverse par job old $CYTH
0 · Reply
DottoreMK
DottoreMK May. 9 at 4:16 PM
$CYTH
0 · Reply
Miko_Vakilla
Miko_Vakilla Apr. 7 at 8:39 PM
$CYTH Form 15! $2.15 here we come. Let&#39;s go Mo!
1 · Reply
GDS_investing
GDS_investing Apr. 7 at 6:06 PM
$RFL money on the floor add here today for 5$+ $CYTH
0 · Reply
StreetSlap
StreetSlap Apr. 6 at 7:03 AM
$ANVS $CYTH $CEIN $IMUX $PTPI Lol Nah...great retail hunters, great scammers, but Maria just set the bar to a new low 🐍💃🏻
1 · Reply
ForestFoxes
ForestFoxes Apr. 6 at 12:27 AM
$ANVS $CYTH $CEIN $IMUX $PTPI @StreetSlap🤯 ⁿᵒ ʷᵃʸ ... 🤨 ᵃʳᵉ ʸᵒᵘ ᵗᵉˡˡᶦⁿᵍ ᵐᵉ ᵗʰᵃᵗ ᵗʰᵒˢᵉ ᶜᴱᴼˢ ... ᵃˡˢᵒ ʰᵉˡᵈ ᵃ ᴾᵃᵗᶦᵉⁿᵗˢ&#39; ᴸᶦᵛᵉ ᶠᵒʳᵘᵐ and, told patients and their families to &quot;BUY Stock!&quot; and &quot;That&#39;s the ONLY out of it!&quot; 💔 Did those other CEOs also use fiery language in their chat with patients and families with references to Hell repeated??? 🔥🐍😈🔥
1 · Reply
StreetSlap
StreetSlap Apr. 5 at 9:56 PM
$ANVS Golden rule ! Saw that so many times...$CYTH (Scott Fine) $CEIN (James Doris) $IMUX (Daniel Vitt) $PTPI (Fady Boctor) just to name a few
0 · Reply
JoeLogan
JoeLogan Apr. 4 at 4:55 PM
$CYTH My man Scott and fam after receiving donations from baggies all years round.
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 31 at 7:10 PM
$ICCT code change adding $CYTH 1.52***** super filler created 2024!
2 · Reply
MK2020
MK2020 Mar. 30 at 9:58 PM
$CYTH What I also see as important, but which is not currently in focus, is that if the NPC mediament works, this is also very positive for the Alzheimer&#39;s study.
0 · Reply
Looserman
Looserman Mar. 30 at 6:46 AM
$CYTH How many shares will I get for my 1,200 shares ?
1 · Reply
LC_Investor
LC_Investor Mar. 28 at 8:06 PM
$CYTH
0 · Reply
northmark1
northmark1 Mar. 28 at 11:55 AM
$CYTH Well I got Ripped off. Only got one share of RFL for everyone of my Cyth shares. Bullshit Deal. Was supposed to be shares of RFL for every Cyth.
2 · Reply
Hickory68
Hickory68 Mar. 27 at 3:16 PM
$CYTH Still showing I own $CYTH when will my stocks convert?
1 · Reply
Miko_Vakilla
Miko_Vakilla Mar. 27 at 2:43 PM
$CYTH The Fine family made a killing on this one. Stripped the value straight out of the hands of the equity owners. @M_W_T
0 · Reply
Curate
Curate Mar. 27 at 1:35 PM
$CYTH my shares have converted. In with over 5000 of $RFL shares at a ridiculous average price each. Will try to dollar costs average this down in time cause I’m still holding out on this molecule!
4 · Reply
CaseOfTheYips1
CaseOfTheYips1 Mar. 27 at 1:34 PM
$CYTH will be my last posts here. Shares converted and I’m now looking at $10.78 to break even… still going to grandma’s house, just had to change vehicles… 🤞🤞🥃
3 · Reply
yilayan1980
yilayan1980 Mar. 27 at 10:06 AM
$CYTH what happens if you own shares ??
1 · Reply